PharmTech News

Articles

Takeda is divesting the products because they are outside of Takeda’s current business focus, which includes gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. 

Takeda to Divest Select Diabetes Products in Japan to Teijin Pharma for $1.2 Billion

Distribution of the first one-dose vaccine for COVID-19 to start in early March.

J&J Vaccine Approved for Emergency Use

Through the acquisition, Merck will have access to Pandion’s pipeline of precision immune modulators targeting critical immune control nodes, including its lead candidate, PT101.

Merck to Acquire Pandion Therapeutics for $1.85 Billion

The companies will co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.

Eli Lilly to Collaborate with Rigel Pharmaceuticals for $960 Million 

The acquisition will allow Charles River to expand its cell and gene therapy development, testing, and manufacturing capabilities, while adding to its existing portfolio of non-clinical capabilities.

Charles River to Acquire Cognate BioServices for $875 Million

The US government will pay $1.95 billion for the additional 100 million doses, bringing the total number of doses supplied by the companies up to 300 million.

Pfizer and BioNTech to Supply 100 Million Additional Doses of COVID-19 Vaccine to United States

The company has pleaded guilty to violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to FDA investigators and will pay a criminal fine of $30 million, and forfeit an additional $20 million.

Fresenius Kabi Oncology Pleads Guilty to Concealing and Destroying Records Prior to FDA Inspection

MTEM will handle research activities for the discovery of the next generation of engineered toxin bodies using its ETB platform, while Bristol Myers Squibb will obtain a license to develop and commercialize the ETBs.

Bristol Myers Squibb and Molecular Templates Form $1.37-Billion R&D Collaboration

The company has divested its specialty ingredients business and operations to Bain Capital and Cinven, two private equity firms.

Lonza to Divest its Specialty Ingredients Business and Operations for $4.2 Billion

FDA considers regulatory flexibility to allow the agency and sponsors to adapt and pivot to changes in coronavirus. 

Top News